Methotrexate maintenance therapy and quality of life during the targeted therapy era in rheumatoid arthritis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Descriptive study assesses drug persistence and quality of life in RA patients on combination therapy, suggesting important predictive factors.

MTX maintenance therapy was achieved in 36.84% to 88% of patients depending on therapy type.
The DAS-28 score showed significant improvement from 6.6 at baseline to 2.9, indicating reduced disease activity.
Combination therapy did not significantly improve quality of life compared to monotherapy, despite better joint outcomes.
Predictive factors influencing MTX persistence included high baseline DAS-28 and demographics like age and gender.

Abdellaoui et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Descriptive study assesses drug persistence and quality of life in RA patients on combination therapy, suggesting important predictive factors.